Document Detail

The determination of additive effect and intraocular pressure lowering effects of 0.05% bromocriptine and 0.25% timolol.
MedLine Citation:
PMID:  9112164     Owner:  NLM     Status:  MEDLINE    
It has been confirmed that topically applied bromocriptine has a satisfactory intraocular pressure (IOP) lowering effect without serious ocular or systemic side effects. We compared the IOP lowering effects of 0.05% bromocriptine and 0.25% timolol and determined whether they have an additive effect in lowering IOP in normal volunteers. In a double-blind, randomised, prospective, single-dose study, we measured IOP in 24 ocular normotensive subjects before (baseline) and 2, 4 and 6 hours after topical instillation of the following drugs: timolol and bromocriptine alone (n: 14), timolol+bromocriptine, timolol+placebo, bromocriptine+placebo (n: 10). Both bromocriptine and timolol have a significant IOP lowering effect (p < 0.01) compared with the baseline value during the study period. There were no significant differences in IOP lowering effect between timolol and bromocriptine at 2 and 4 hours (p > 0.05), but timolol was more efficacious than bromocriptine at 6 hours (p < 0.05). An additive effect in lowering IOP was not found. Although timolol and bromocriptine have no additive effect in lowering IOP, topically applied bromocriptine may be used in the treatment of glaucoma.
O Elibol; C Güler; K Arici; A Topalkara; S Demircan
Related Documents :
17494954 - Novel pressure-to-cornea index in glaucoma.
7088504 - Intraocular pressure status in 100 consecutive patients with exfoliation syndrome.
17024224 - Intraocular pressure before and after visual field examination.
11417334 - Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressur...
17711734 - Associations of blood pressure and arterial compliance with occupational noise exposure...
17142824 - Pressure support ventilation during fibreoptic intubation under propofol anaesthesia.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International ophthalmology     Volume:  20     ISSN:  0165-5701     ISO Abbreviation:  Int Ophthalmol     Publication Date:    1996-1997
Date Detail:
Created Date:  1997-07-17     Completed Date:  1997-07-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7904294     Medline TA:  Int Ophthalmol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  53-5     Citation Subset:  IM    
Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Adrenergic beta-Antagonists / administration & dosage*
Bromocriptine / administration & dosage*
Dopamine Agonists / administration & dosage*
Double-Blind Method
Drug Evaluation
Drug Synergism
Follow-Up Studies
Intraocular Pressure / drug effects*
Ophthalmic Solutions
Prospective Studies
Reference Values
Timolol / administration & dosage*
Tonometry, Ocular / methods
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Dopamine Agonists; 0/Ophthalmic Solutions; 25614-03-3/Bromocriptine; 26839-75-8/Timolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ocular hypotensive effect of sublingual administration of timolol.
Next Document:  The effects of antiglaucomatous agents on conjunctiva used for various durations.